 Zynerba Pharmaceuticals NASDAQ:ZYNE Inc said it has entered into an equity purchase agreement for up to 20 million with Chicago-based institutional investor Lincoln Park Capital Fund LLC LPC, in a move that will provide the company with financial flexibility in the clinical development of its Zygel CBD gel. Under the terms of the deal, Zynerba will have the right, but not the obligation, to sell to LPC up to 20 million worth of shares of its common stock over the 36-month term of the agreement. 